Next Article in Journal
Methyl 5′-Chloro-8-formyl-5-hydroxy-1′,3′,3′-trimethyl-spiro-[chromene-2,2′-indoline]-6-carboxylate
Previous Article in Journal
4-Amino-5-benzoyl-1-benzyl-2-(4,5,6,7-tetrahydro-1H-indol-2-yl)-1H-pyrrole-3-carbonitrile
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molbank
Volume 2023
Issue 1
10.3390/M1548
molbank-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

2-{[4-(4-Bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

by
Monika Wujec
1,* and
Rafał Typek
2,*
1
Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland
2
Department of Chromatography, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Sklodowska University in Lublin, 20-031 Lublin, Poland
*
Authors to whom correspondence should be addressed.
Molbank 2023, 2023(1), M1548; https://doi.org/10.3390/M1548
Submission received: 12 December 2022 / Revised: 28 December 2022 / Accepted: 10 January 2023 / Published: 12 January 2023
(This article belongs to the Section Organic Synthesis and Biosynthesis)
Browse Figure
Review Reports Versions Notes

Abstract

:
The novel compound 2-{[4-(4-bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione is obtained in good yield via a three-step protocol. The product’s structure is assigned by HRMS, IR, 1H and 13C NMR experiments.

1. Introduction

Piperazine is a common structural motif found in agrochemicals and pharmaceuticals, in part due to its ability to positively modulate the pharmacokinetic properties of a drug substance. The incorporation of this heterocycle into biologically active compounds can be accomplished through a Mannich reaction [1]. Piperazine can be found in biologically active compounds for a variety of disease states, such as antihistamines, antiparasitic, antifungal, antibacterial, antiviral, antipsychotic, antidepressant, anti-inflammatory, anticoagulant, antitumor, and antidiabetic drugs [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26]. Additionally, the piperazine ring is a component in potential treatments for Parkinson’s and Alzheimer’s disease [27,28,29,30,31], and known antibiotic drugs Ciprofloxacin and Ofloxacin. Moreover, they are also used as psychoactive substances used illegally for recreational purposes [32,33].
We previously described some new derivatives of 1,2,4-triazole with piperazine moiety, some of which exhibited good antibacterial activity [34].
Herein, we report on the synthesis and characterization of a novel Mannich derivative with promising antibacterial activity.

2. Results and Discussion

The title compound 2-{[4-(4-bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione is obtained via a four-step protocol, shown in Scheme 1. The 1,2,4-triazole derivative is prepared in the very simple and efficient procedure described previously [35]. The reaction with amine was carried out in 95% ethanol at room temperature for 24 h. The progress of the reaction was checked by TLC chromatography using the mixture CHCl3: C2H5OH (10:1 v/v) as eluent.
The structure of the new Mannich base is assigned by HRMS, IR, 1H, and 13C NMR spectra (see Supplementary Materials). The 1H spectrum in DMSO-d6 shows characteristic signals for the protons of piperazine at 2.96 and 3.16 ppm, respectively, protons of the methoxy group as a singlet at 3.75 ppm, the signal of the CH2 group at 5.23 as a singlet, and aromatic protons in the range 6.92–7.67. There is a lack of signal characteristics for the proton NH group present in the spectrum of the initial compound. In the 13C NMR spectra, carbons signals were observed at expected values of chemical shift. The six aliphatic carbon were observed as four signals at 48.46, 50.14, 55.81, and 69.21 ppm. The IR spectra of products show a characteristic band for CH aliphatic and aromatic stretch at 2883 cm−1, 2831 cm−1, and 3040 cm−1, respectively.

3. Materials and Methods

3.1. General

All reagents were purchased from Merck (Darmstadt, Germany) and were used without any further purification. Solvents (ethanol, dry ethanol, diethyl ether, chloroform) were used as purchased (POCH Gliwice, Poland). Merck silica gel (TLC-cards with fluorescent indicator 254 nm) was used for TLC chromatography. The NMR spectra were recorded on a Bruker Avance 600 spectrometer (Rheinstetten, Germany) in DMSO-d6; the chemical shifts were quoted in ppm in δ-values and the coupling constants were calculated in Hz. The spectra were processed with the Topspin 3.6.2 program. The IR spectra were measured on a Spectrometer FT-IR Nicolett 8700 (Thermo Scientific, Waltham, MA, USA).
The chromatographic measurements were performed using LC/MS system consisting of UHPLC chromatograph (UltiMate 3000, Dionex, Sunnyvale, CA, USA) connect whit the linear trap quadrupole-Orbitrap mass spectrometer (LTQ-Orbitrap Velos from Thermo Fisher Scientific, San Jose, CA, USA) equipped with ESI source. In all analyses a Gemini C18 column (4.6 × 100 mm, 3 µm) (Phenomenex, Torrance, CA, USA) was used for chromatographic separation.

3.2. Synthesis of 2-{[4-(4-Bromophenyl)piperazin-1-yl]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

3.2.1. Synthesis of 4-Methoxybenzhydrazide [35]

Ethyl 4-methoxybenzoate (1 mmol, 0.18 g) was dissolved in 5 mL of 96% ethanol and hydrazine hydrate (100%) (2 mL) was added. The mixture was refluxed for 3 h. After the completion of the reaction by TLC (toluene:ethyl acetate = 7:3 v/v), the solution was cooled and the precipitate was filtered off and dried. 4-Methoxybenzhydrazide was obtained with 85% yield (0.14 g).

3.2.2. Synthesis of 4-(3-Chlorophenyl)-1-(4-methoxyphenyl)thiosemicarbazide [35]

In the next step, hydrazide (1 mmol, 0.17 g) and 3-chlorophenyl isothiocyanate (1 mmol, 0.13 mL) was refluxed for 2 h in anhydrous ethanol (5 mL). Then, the solution was cooled to room temperature. The solid product was filtered off, washed with hot water and diethyl ether, dried, and crystallized from 96% ethanol.

3.2.3. Synthesis of 4-(3-Chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione [35]

The obtained thiosemicarbazide derivative (0.31 g, yield 90%) was refluxed with 2% NaOH solution for 4 h. Next, the solution was cooled and acidified (6N HCl). The solid product was filtered and crystallized from 96% ethanol. 4-(3-Chlorophenyl)-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione was obtained as a white solid to yield 0.22 g (70%). M.p. 261–262 °C.

3.2.4. Synthesis of 2-{[4-(4-Bromophenyl)piperazin-1-yl]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

A total of 1 mmol (0.32 g) of the 4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione was dissolved in 10 mL anhydrous ethanol and then 4-(4-bromophenyl)piperazine (1 mmol, 0.24 g) and a formaldehyde solution (aq. 37 %, 5 drops) were added. The mixture was stirred at room temperature for 1 h. The appearance of the product was observed. However, the complete reaction of the substrates took place after 24 h at room temperature. The progress of the reaction was checked by TLC chromatography (eluent chloroform:96% ethanol, 10:1 v/v). The precipitate was filtered off, dried, and crystallized from 96 % ethanol.
Yield: 81 %, 0.46 g. White crystals, m.p.: 226–227 °C. 1H NMR (600 MHz (d6)DMSO): 2.95–2.97 (m, 4H, 2CH2 piperazine,), 3.15–3.17 (m, 4H, 2CH2 piperazine), 3.75 (s, 3H, CH3) 5.25 (s, 2H, N-CH2,), 6.90 (d, 2H, ArH, J = 9.1 Hz), 6.95 (d, 2H, ArH, J = 8.9 Hz), 7.29 (d, 2H, ArH, J = 8.9 Hz), 7.34 (d, 2H, ArH, J = 9.1 Hz), 7.37–7.38 (m, 1H, ArH), 7.53 (t, 1H, ArH, J = 8.0 Hz), 7.58–7.60 (m, 1H, ArH), 7.67 (t, 1H, ArH, J = 2.0 Hz). 13C NMR (600 MHz, (d6)DMSO): 48.46, 50.14, 55.81, 69.21, 110.56, 114.60, 117.73, 117.96, 128.31, 129.61, 130.16, 130,55, 131.39, 131.94, 133.77, 136.96, 149.36, 150.69, 161.33, 169.72. IR (KBr, cm−1): 3040 (CHarom.), 2883, 2831 (CHaliph.), 1326 (C=S). HRMS (ESI), m/z: calcd for C26H25BrClN5OS. Theoretical mass [M + H]+ 570.07300, Experimental mass [M + H]+ 570.07309.

4. Conclusions

2-{[4-(4-bromophenyl)piperazin-1-yl]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione is obtained in good yield by aminomethylation reaction of 4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione with 4-(4-bromophenyl)piperazine and formaldehyde. The product is purified by crystallization from 96% ethanol and characterized by 1H NMR, 13C NMR, IR, and HRMS spectra.

Supplementary Materials

The following are available online: 1H, 13C NMR, and IR spectra.

Author Contributions

The synthetic experiments and NMR analyses were carried out by M.W. The HRMS was performed by R.T., and M.W. contributed in the discussion of the results and in the manuscript writing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank student Lidia Jaskowska for the synthesis of one compound.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gul, H.I.; Tugrak, M.; Gul, M.; Mazlumoglu, S.; Sakagami, H.; Gulcin, I.; Supuran, T. New phenolic Mannich bases with piperazines and their bioactivities. Bioorg. Chem. 2019, 90, 103057. [Google Scholar] [CrossRef]
  2. Hafeez, F.; Zahoor, A.F.; Rasul, A.; Ahmad, S.; Mansha, A. Synthesis and anticancer evaluation of 2-oxo-2-(arylamino)-ethyl 4- phenylpiperazine-1-carbodithioates. Pak. J. Pharm. Sci. 2021, 34, 353–357. [Google Scholar] [PubMed]
  3. Al-Soud, Y.A.; Alhelal, K.A.S.; Saeed, B.A.; Abu-Qatouseh, L.; Al-Suod, H.H.; Al-Ahmad, H.; Al-Masoudi, N.A.; Al-Qawasmeh, R.A. Synthesis, anticancer activity and molecular docking studies of new 4-nitroimidazole derivatives. Arkivoc 2021, 8, 296–309. [Google Scholar] [CrossRef]
  4. Zárate, A.M.; Espinosa-Bustos, C.; Guerrero, S.; Fierro, A.; Oyarzún-Ampuero, F.; Quest, A.F.G.; Di Marcotullio, L.; Loricchio, E.; Caimano, M.; Calcaterra, A.; et al. A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo. Int. J. Mol. Sci. 2021, 22, 8372. [Google Scholar] [CrossRef] [PubMed]
  5. Abba, C.; Puram, N.; Betala, S. Synthesis of Novel Amide Functionalized Pyrido[2,3-d]pyrimidine Derivatives and their Anticancer Activity. Asian J. Chem. 2021, 33, 1579–1584. [Google Scholar] [CrossRef]
  6. Alagöz, M.A.; Özdemir, Z.; Uysal, M.; Carradori, S.; Gallorini, M.; Ricci, A.; Zara, S.; Mathew, B. Synthesis, Cytotoxicity and Anti-Proliferative Activity against AGS Cells of New 3(2H)-Pyridazinone Derivatives Endowed with a Piperazinyl Linker. Pharmaceuticals 2021, 14, 183. [Google Scholar] [CrossRef]
  7. Kaczor, A.; Szemerédi, N.; Kucwaj-Brysz, K.; Dąbrowska, M.; Starek, M.; Latacz, G.; Spengler, G.; Handzlik, J. Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able to Overcome ABCB1-Based Multidrug Resistance. ChemMedChem 2021, 16, 2386–2401. [Google Scholar] [CrossRef]
  8. Liu, X.; Wang, Y.; Wang, X.; Zhang, Z. Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents. Bioorg. Med. Chem. 2021, 46, 116390. [Google Scholar] [CrossRef]
  9. Sowmithri, S.; Kumar, J.V.S.; Mahesh, P.; Krishnamohan, T. Design and Synthesis of Novel Piperazine (2-Chloroethyl)-1-nitrosourea Analogues as Anticancer Agents. Asian J. Chem. 2022, 34, 591–596. [Google Scholar] [CrossRef]
  10. Baker, J.R.; Russel, C.C.; Gilbert, J.; McCluskey, A.; Sakoff, J.A. Amino alcohol acrylonitriles as broad spectrum and tumour selective cytotoxic agents. RSC Med. Chem. 2021, 12, 929–942. [Google Scholar] [CrossRef]
  11. Severin, A.O.; Pilyo, S.G.; Potikha, L.M.; Brovarets, V.S. Synthesis and Antitumor Activity of 5-Phenyl-1,3-thiazole-4-sulfonamide Derivatives. Russ. J. Gen. Chem. 2022, 92, 174–184. [Google Scholar] [CrossRef]
  12. Elgawish, M.S.; Nafie, M.S.; Yassen, A.S.A.; Yamada, K.; Ghareb, N. The design and synthesis of potent benzimidazole derivatives via scaffold hybridization and evaluating their antiproliferative and proapoptotic activity against breast and lung cancer cell lines. New J. Chem. 2022, 46, 4239. [Google Scholar] [CrossRef]
  13. Patel, S.; Globisch, C.; Pulugu, P.; Kumar, P.; Jain, A.; Shard, A. Novel imidazopyrimidines-based molecules induce tetramerization of tumor pyruvate kinase M2 and exhibit potent antiproliferative profile. Eur. J. Pharm. Sci. 2022, 170, 106112. [Google Scholar] [CrossRef]
  14. Song, J.; Liu, Y.; Yuan, X.Y.; Liu, W.B.; Li, Y.R.; Yu, G.X.; Tian, X.Y.; Zhang, Y.B.; Fu, X.J.; Zhang, S.Y. Discovery of 1,2,4-triazine dithiocarbamate derivatives as NEDDylation agonists to inhibit gastric cancers. Eur. J. Med. Chem. 2021, 225, 113801. [Google Scholar] [CrossRef]
  15. Rzycka-Korzec, R.; Malarz, K.; Gawecki, R.; Mrozek-Wilczkiewicz, A.; Małecki, J.G.; Schab-Balcerzak, E.; Korzec, M.; Polanski, J. Effect of the complex-formation ability of thiosemicarbazones containing (aza)benzene or 3-nitro-1,8-naphthalimide unit towards Cu(II) and Fe(III) ions on their anticancer activity. J. Photochem. Photobiol. A 2021, 415, 113314. [Google Scholar] [CrossRef]
  16. Silalai, P.; Pruksakorn, D.; Chairoungdua, A.; Suksen, K.; Saeeng, R. Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line. Bioorg. Med. Chem. Lett. 2021, 45, 128135. [Google Scholar] [CrossRef]
  17. Desai, N.C.; Rupala, Y.M.; Khasiya, A.G.; Shah, K.N.; Pandit, U.P.; Khedkar, V.M. Synthesis, biological evaluation, and molecular docking study of thiophene-, piperazine-, and thiazolidinone-based hybrids as potential antimicrobial agents. J. Heterocyclic. Chem. 2022, 59, 75–87. [Google Scholar] [CrossRef]
  18. Baker, J.R.; Cossar, P.J.; Blaskovich, M.A.T.; Elliott, A.G.; Zuegg, J.; Cooper, M.A.; Lewis, P.J.; McCluskey, A. Amino Alcohols as Potential Antibiotic and Antifungal Leads. Molecules 2022, 27, 2050. [Google Scholar] [CrossRef]
  19. Foks, H.; Janowiec, M.; Zwolska, Z.; Augustynowicz-Kopeć, E. Synthesis and Tuberculostatic Activity of Some 2-Piperazinmethylene Derivatives 1,2,4-Triazole-3-Thiones. Phosphorus Sulfer Silicon 2005, 180, 537–543. [Google Scholar] [CrossRef]
  20. Sutherland, H.S.; Lu, G.; Tong, A.S.T.; Conole, D.; Franzblau, S.G.; Upton, A.M.; Lotlikar, M.U.; Cooper, C.B.; Palmer, B.D.; Choi, P.J.; et al. Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis. Eur. J. Chem. 2022, 229, 114059. [Google Scholar] [CrossRef]
  21. Patel, A.B.; Rohit, J.V. Development of 1,3,4-Thiadiazole and Piperazine Fused Hybrid Quinazoline Derivatives as Dynamic Antimycobacterial Agents. Polycycl. Aromat. Compd. 2022, 42, 5991–6002. [Google Scholar] [CrossRef]
  22. Varpe, B.D.; Jadhav, S.B. Schiff Base Conjugate of 5-Fluoroisatin with Thiophene-2-Ethylamine and its Mannich Bases: Synthesis, Molecular Docking, and Evaluation of in vitro Anti-inflammatory and Anti-tubercular Activity. Int. J. Pharm. Investig. 2021, 11, 189–194. [Google Scholar] [CrossRef]
  23. Gharbi, C.; Toumi, B.; Soudani, S.; Lefebvre, F.; Kaminsky, W.; Jelsch, C.; Nasr, C.B.; Khedhiri, L. Synthesis, structural characterization, antibacterial activity, DFT computational studies and thermal analysis of two new thiocyanate compounds based on 1-phenylpiperazine. J. Mol. Struct. 2022, 1257, 132620. [Google Scholar] [CrossRef]
  24. Plescia, C.B.; Lindstrom, A.R.; Quintero, M.V.; Keiser, P.; Anantpadma, M.; Davey, R.; Stahelin, R.V.; Davisson, V.J. Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry. ACS Infect. Dis. 2022, 8, 942–957. [Google Scholar] [CrossRef]
  25. Mishra, S.; Parmar, N.; Chandrakar, P.; Sharma, C.P.; Parveen, S.; Vats, R.P.; Seth, A.; Goel, A.; Kar, S. Design, synthesis, in vitro and in vivo biological evaluation of pyranone-piperazine analogs as potent antileishmanial agents. Eur. J. Med. Chem. 2021, 221, 113516. [Google Scholar] [CrossRef]
  26. Kucwaj-Brysz, K.; Dela, A.; Podlewska, S.; Bednarski, M.; Siwek, A.; Satała, G.; Czarnota, K.; Handzlik, J.; Kiec-Kononowicz, K. The Structural Determinants for α1-Adrenergic/ Serotonin Receptors Activity aong PhenylpiperazineHydantoin Derivatives. Molecules 2021, 26, 7025. [Google Scholar] [CrossRef]
  27. Ji, L.; Fang, Y.; Tang, J.; Liu, C.; Huang, C.; Hu, Q.; Li, Q.; Chen, Z. Synthesis and biological evaluation of 18F-labelled dopamine D3 receptor selective ligands. Bioorg. Med. Chem. 2022, 62, 128630. [Google Scholar] [CrossRef]
  28. Lee, B.; Taylor, M.; Griffin, S.A.; McInnis, T.; Sumien, N.; Mach, R.H.; Luedtke, R.R. Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands. Molecules 2021, 26, 3182. [Google Scholar] [CrossRef]
  29. Waly, O.M.; Saad, K.M.; El-Subbagh, H.I.; Bayomi, S.M.; Ghaly, M.A. Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer’s agents. Eur. J. Med. Chem. 2022, 231, 114152. [Google Scholar] [CrossRef]
  30. Mohammadi-Khanaposthani, M.; Nori, M.; Valizadeh, Y.; Javanshir, S.; Dastyafteh, N.; Moaazam, A.; Hosseini, S.; Larijani, B.; Adibi, H.; Biglar, M.; et al. New 4-phenylpiperazine-carbodithioate-N-phenylacetamide hybrids: Synthesis, in vitro and in silico evaluations against cholinesterase and α-glucosidase enzymes. Arch. Pharm. 2022, 355, 2100313. [Google Scholar] [CrossRef]
  31. Ansari, S.; Noori, M.; Pedrood, K.; Mohammadi-Khanaposhtani, M.; Moazzam, A.; Hosseini, S.; Larijani, B.; Adibi, H.; Biglar, M.; Hamedifar, H.; et al. Novel aryl(4-phenylpiperazin-1-yl)methanethione derivatives as new anti-Alzheimer agents: Design, synthesis, in vitro and in silico assays. J. Mol. Struct. 2022, 1262, 132945. [Google Scholar] [CrossRef]
  32. Kumar, R.R.; Sahu, B.; Pathania, S.; Singh, P.K.; Akhtar, M.J.; Kumar, B. Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure-Activity Relationships. ChemMedChem 2021, 16, 1878–1901. [Google Scholar] [CrossRef] [PubMed]
  33. Adamczyk-Woźniak, A.; Czerwińska, K.; Madura, I.D.; Matuszewska, A.; Sporzyński, A.; Żubrowska-Zembrzuska, A. Piperazine derivatives of boronic acids—Potential bifunctional biologically active compounds. New J. Chem. 2015, 39, 4308–4315. [Google Scholar] [CrossRef]
  34. Paneth, A.; Trotsko, N.; Popiolek, Ł.; Grzegorczyk, A.; Krzanowski, T.; Janowska, S.; Malm, A.; Wujec, M. Synthesis and Antibacterial Evaluation of Mannich Bases Derived from 1,2,4-Triazole. Chem. Biodivers. 2019, 16, e1900377. [Google Scholar] [CrossRef] [PubMed]
  35. Swarnagowri, N.; Santosh, G.L.; Sushruta, S.H.; Swapna, B.; Nitinkumar, S.S. Synthesis, molecular docking and evaluation of library of 3-mercapto-1,2,4-triazole derivatives as antimicrobial agents. Asian J. Chem. 2021, 33, 3039–3046. [Google Scholar]
Molbank 2023 m1548 sch001 550
Scheme 1. Synthesis of 2-{[4-(4-bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione.
Scheme 1. Synthesis of 2-{[4-(4-bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione.
Molbank 2023 m1548 sch001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wujec, M.; Typek, R. 2-{[4-(4-Bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione. Molbank 2023, 2023, M1548. https://doi.org/10.3390/M1548

AMA Style

Wujec M, Typek R. 2-{[4-(4-Bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione. Molbank. 2023; 2023(1):M1548. https://doi.org/10.3390/M1548

Chicago/Turabian Style

Wujec, Monika, and Rafał Typek. 2023. "2-{[4-(4-Bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione" Molbank 2023, no. 1: M1548. https://doi.org/10.3390/M1548

APA Style

Wujec, M., & Typek, R. (2023). 2-{[4-(4-Bromophenyl)piperazin-1-yl)]methyl}-4-(3-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione. Molbank, 2023(1), M1548. https://doi.org/10.3390/M1548

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop